(Q43417536)

English

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617.

scientific article published in July 2000

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. (English)

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

Frederick R. Appelbaum

16

object named as

F R Appelbaum

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Cheryl L. Willman

15

object named as

C L Willman

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

author name string

T R Chauncey

1

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C Rankin

2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

J E Anderson

3

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

I Chen

4

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

K J Kopecky

5

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

J E Godwin

6

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M E Kalaycio

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D F Moore

8

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

M S Shurafa

9

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

S H Petersdorf

10

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

E H Kraut

11

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

C P Leith

12

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

D R Head

13

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

F W Luthardt

14

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

publication date

1 July 2000

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Leukemia Research

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

567-574

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute myeloid leukaemia in the elderly: biology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of treatment failure in acute nonlymphocytic leukemia patients over fifty years of age. A Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacological considerations in the modulation of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of multidrug resistance: at the threshold

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leuk

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia--an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2800%2900024-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0145-2126(00)00024-2

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

23 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43417536&oldid=1611737568"